When Will Exparel Become Available as a Generic?
Generic versions of Exparel (bupivacaine liposome injectable emulsion) are anticipated to become available in 2026, following the expiration of key patents and exclusivity periods [1]. The drug's primary patent is set to expire in April 2026 [2].
What Exclusivity Protections Does Exparel Have?
Exparel benefits from several layers of exclusivity. Beyond its listed patents, the U.S. Food and Drug Administration (FDA) has granted it 3-year new clinical data exclusivity, which typically expires in October 2023, and 7-year orphan drug exclusivity, which expired in October 2020 [3].
What is the Status of Exparel Patent Litigation?
The patent landscape for Exparel has been subject to legal challenges. As of late 2023, litigation concerning Exparel patents was ongoing, which could potentially impact the timeline for generic entry [4].
Who is Developing Generic Alternatives to Exparel?
Multiple pharmaceutical companies are actively pursuing the development of generic versions of Exparel. Companies like Teva Pharmaceuticals and Alphanov are among those that have submitted Abbreviated New Drug Applications (ANDAs) for generic bupivacaine liposome injectable emulsion [5][6].
How Does Exparel Work and What is It Used For?
Exparel is a long-acting local anesthetic. It is a liposomal formulation of bupivacaine that provides pain relief for up to 72 hours [1]. It is commonly used to manage post-surgical pain and in certain orthopedic procedures [7].
What is the Expected Impact of Generic Exparel on Pricing?
The introduction of generic competition is generally expected to lead to a significant decrease in the price of Exparel. This will likely make the treatment more accessible for healthcare providers and patients [2].
How Does Exparel Compare to Immediate-Release Bupivacaine?
Exparel's liposomal formulation allows for sustained release of bupivacaine, providing a longer duration of pain relief compared to immediate-release bupivacaine formulations. This extended effect is a key differentiator and contributes to its use in situations requiring prolonged analgesia [1][7].
Sources:
[1] DrugPatentWatch.com
[2] https://drugpatentwatch.com/blog/exparel-generic-launch-date-patent-expiry
[3] https://drugpatentwatch.com/drug/exparel
[4] https://drugpatentwatch.com/drug/exparel/litigation
[5] https://drugpatentwatch.com/drug/exparel/generics/teva-pharmaceuticals
[6] https://drugpatentwatch.com/drug/exparel/generics/alphanove
[7] https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203094s014lbl.pdf